Diagonal Bio AB ("Diagonal Bio" or "the Company"), with its point-of-care analysis system LAMPlify®, has filed a patent application with the Swedish Intellectual Property Office (PRV). The patent covers a novel computational method that significantly improves the design of LAMP primers – a critical component in molecular analysis. This innovative method enables the creation of more effective primers than existing methods and reduces both time and human resources.
The filed patent application supports Diagonal Bio's commitment to deliver faster and more reliable analysis at the point-of-care. The technology used in LAMPlify utilises a set of 4-6 primers to amplify a particular genetic marker, creating a test that is specific to an individual pathogen or organism. Traditionally, designing this set of primers is a labour- and resource intensive process, which requires substantial expert insights. Diagonal Bio's novel computational algorithm utilises a unique design method and automates the process. The result of this is superior primers and superior tests in considerably less man-hours compared with traditional methods.
This novel computational method is also applicable to traditional LAMP technology.
"This technology is a cornerstone of our R&D pipeline. By integrating this method into our development process, we've been able to reduce the time it takes to create new point-of-care tests from many months down to just a few weeks. It's a gamechanger for speed, efficiency and being able to respond quickly to customer needs or new developments in the global health space. This patent application protects our innovation and enables Diagonal Bio to be more collaborative with a wider range of external experts during the test design process, potentially opening up a more diverse customer base", says Karin Wehlin, CEO at Diagonal Bio AB.
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.